Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Related Posts
Auto & Transport Roundup: Market Talk
- staff
- January 7, 2025
- 0
Read about Tesla, European airlines and more in the latest Market Talks covering the Auto and Transport sector.
Basic Materials Roundup: Market Talk
Read about BHP, South32 and more in the latest Market Talks covering Basic Materials.
PPG to Cut 1,800 Jobs, Shrink Costs With Sale of Architectural-Coatings Biz
PPG agreed to sell its architectural-coatings business in the U.S. and Canada to private-equity firm American Industrial Partners for $550 million, and outlined cost and […]